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INTRODUCTION
According to the Biomarkers Definitions Working 
Group1, a biomarker is defined as “a characteristic that 
is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes 
or pharmacologic responses to a therapeutic interven-
tion”. Tumour markers are molecules produced by can-
cer cells and either endogenously present in the cellular 
compartments of cancer cells or are secreted from the 
cells. They are measured in blood, urine, stool, body flu-
ids (e.g. pancreatic cyst fluid) or tissues of patient with 
cancer. Tumour markers are often proteins but genetic 
changes (gene mutations) and changes in gene expres-
sion patterns are also used as tumour biomarkers. The 
alterations in the tumour biomarkers help in the cate-
gorisation of patients into distinct groups2.
Biomarkers are used in the clinical management of 
patients with tumours and can broadly be classified as: 
susceptibility biomarkers that help in the identification 
of individuals at risk of developing cancer; screening 
biomarkers that help in the early detection of cancer in 
the general or at risk populations of developing overt 
disease (i.e. detects subclinical disease); diagnostic bio-
markers that help in the diagnosis of patients with the 
disease; prognostic biomarkers that help to predict the 
course of disease (e.g. survival); predictive biomarkers 
that help to predict response to therapy (e.g. a drug 
or surgical intervention) or monitor the efficacy of a 
therapy1,3-5; and pharmacogenomics biomarkers which 
are “measurable DNA and/or RNA characteristics that 
are indicators of normal biologic processes, pathogen-
ic processes and/or a response to therapeutic or other 
interventions”6. Some of these markers are already used 
in routine clinical practice7-10. Perhaps the earliest mark-
ers to help in the clinical diagnosis were carcinoembry-
onic antigen (CEA) in colon carcinomas11 and prostate 
specific antigen (PSA)12 in prostate cancer.
BIOMARKER DEVELOPMENT
Biomarker development passes through several 
phases of development from discovery to clinical prac-
tice13. It involves a series of identification and validation 
steps before clinical application (Figure 1).
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ABSTRACT
The amount of published literature on biomarkers has exponentially increased 
over the last two decades. Cancer biomarkers are molecules that are either part 
of tumour cells or secreted by tumour cells. Biomarkers can be used for diag-
nosing cancer (tumour versus normal and differentiation of subtypes), prognos-
ticating patients (progression free survival and overall survival) and predicting 
response to therapy. However, very few biomarkers are currently used in clinical 
practice compared to the unprecedented discovery rate. Some of the examples 
are: carcino-embryonic antigen (CEA) for colon cancer; prostate specific antigen 
(PSA) for prostate; and estrogen receptor (ER), progesterone receptor (PR) and 
HER2 for breast cancer. 
Cancer biomarkers passes through a series of phases before they are used in 
clinical practice. First phase in biomarker development is identification of bio-
markers which involve discovery, demonstration and qualification. This is fol-
lowed by validation phase, which includes verification, prioritisation and initial 
validation. More large-scale and outcome-oriented validation studies expedite 
the clinical translation of biomarkers by providing a strong ‘evidence base’. The 
final phase in biomarker development is the routine clinical use of biomarker. 
In summary, careful identification of biomarkers and then validation in well-de-
signed retrospective and prospective studies is a systematic strategy for devel-
oping clinically useful biomarkers.
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1) Identification of biomarkers:
The first phase in biomarker development is the 
identification of suitable candidate biomarkers14. The 
purpose of the identification phase of biomarker de-
velopment is to identify potential candidates with high 
sensitivity for detection. The emphasis therefore is to 
establish the association between biomarker expres-
sion and the tumour of interest. Biomarker identifica-
tion thus uses a significant amount of resources, cost 
and utilizes modern technology. Identification passes 
through the following stages.
a) Discovery: Broadly two approaches can be used for 
biomarker identification. The first approach is to iden-
tify biomarkers based on current knowledge of patho-
physiology of the disease through ‘deductive reason-
ing’. The second approach is using molecular profiling 
techniques to identify candidates based on the differ-
ential expression between tumour and normal tissue13. 
Differentially expressed genes between PDAC and nor-
mal or reactive pancreatic duct are identified through 
high throughput genomic and proteomic studies15,16. 
b) Demonstration: High throughput technologies 
generate a list of potential biomarkers but based on 
different statistical models the biomarker list is further 
refined and selected biomarkers are demonstrated by 
molecular techniques. In carcinoma breast, the differ-
ential expression of genes is demonstrated by DNA 
microarray and polymerase chain reaction17,18, whereas, 
differentially expressed proteins are demonstrated by 
gel electrophoresis and mass spectrometry19-21. 
c) Qualification: The purpose of the qualification is to 
confirm the differential expression of biomarkers using 
alternative techniques such as western blot and immu-
nohistochemistry19-22.
2) Validation of biomarkers:
After identification, the next phase is validation of 
biomarkers which is an important pre-requisite for clini-
cal translation. ‘Omics’ technologies allow identification 
of promising biomarkers but these biomarkers require 
verification, prioritization and validation before they are 
used in clinical practice23.
a) Verification: Biomarker verification is carried out 
to test whether the candidate biomarker has sufficient 
potential for future validation studies. Pilot studies in 
a relatively small sample size are used to investigate 
biomarker expression in both tumour and normal sam-
ples from a variety of patients24,25. Verification begins to 
assess the specificity of biomarkers but still focuses on 
optimum sensitivity13. This helps the researchers to se-
lect more specific candidates that are highly expressed 
in tumour for which they can invest their time, energy 
and money. 
b) Prioritization of candidates: Prioritization of can-
didate biomarkers from a list of potential biomarkers is 
very important for further clinical validation studies due 
to cost and limited clinical resources14. The role of the 
candidate biomarker in tumour biology greatly facilitate 
this selection process as markers involved in the pro-
gression of tumour will prove potentially more useful in 
clinical practice8,26.
c) Validation of selected candidates in large-scale 
studies: Biomarkers achieving a suitably good combi-
nation of sensitivity and specificity from pilot studies in 
the verification and prioritization phases may be select-
ed for further validation in large-scale studies. The fur-
ther validation processes consist of three phases: ana-
lytical validation ensures the intra- and inter-laboratory 
reproducibility of the assay e.g. Immunohistochemistry 
(IHC) achieving similar expression patterns; clinical val-
idation ensures the diagnostic sensitivity and specifici-
ty of the biomarker is consistent for the outcome (e.g. 
differentiation between benign and malignant disease); 
and clinical utility of the biomarker assesses whether it 
improves the diagnostic management of patients27.
Early validation studies are carried out on archival 
pathology specimens (tumour and normal). These sam-
ples are retrospectively identified and used to observe 
the expression and clinical utility of candidate biomark-
ers. These retrospective studies typically overestimate 
the actual sensitivity and specificity of biomarkers. Most 
of the reported literature on biomarker studies uses 
archival pathology samples28,29. However, the clinical 
utility of biomarkers can be more clearly assessed in a 
prospectively designed study. But validation on archival 
samples is a pre-requisite before biomarker investiga-
tion in prospective clinical studies. Prospective clinical 
studies and biomarker trials lead to the qualification of 
biomarker for clinical use. Finally, biomarkers are used 
in clinical practice for the intended clinical use and they 
are monitored for their effectiveness. Figure 1 shows 
the path that a biomarker is likely to take from discov-
ery to clinical use. 
Biomarker validation is therefore an important but 
expensive and lengthy process and depends on the type 
of samples used for assessing the clinical utility. Suc-
cessful implementation of biomarkers in clinical practice 
requires robust evidence from independent validation 
studies. A single study is unlikely to provide sufficient 
evidence for adoption of a biomarker in clinical practice. 
In a study by Ioannidis et al30 the magnitude of the ef-
fect size of proposed biomarkers in highly cited papers 
was examined. It was found that primary studies often 
report a larger effect size compared to the subsequent 
meta-analysis assessing the same associations30. There-
fore, clinical evidence from biomarker studies should be 
interpreted carefully and healthy scepticism is suggest-
ed30. More large-scale and outcome-oriented validation 
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studies expedite the clinical translation of biomarkers 
by providing a strong ‘evidence base’.
IMMUNOHISTOCHEMESTRY
Immunohistochemistry (IHC) is a tissue based meth-
od that allows the visualisation of specific antigens in 
tissues and cellular compartments based on antigen-an-
tibody reaction using microscopy7. IHC remains an im-
portant diagnostic tool even in the era of genomics and 
high throughput molecular diagnostics. IHC was first in-
troduced in the 1960s and since then the amount of lit-
erature has increased exponentially. IHC has been used 
both in research and clinical settings. IHC characterises 
the expression of genes at the protein level and allows 
the observation and localization of protein expression 
simultaneously in tissue and cellular compartments31,32. 
Figure 1: Pathway of biomarker development from discovery to clinical use
Figure Legend: The sequential stages from discovery to clinical diagnostics are shown in the middle vertical 
block. Furthermore, each stage is further elaborated in the right side vertical block.  Adapted from a model 
based on Lee et al 20074.
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It is a routine technique used in diagnostic pathology 
and is relatively inexpensive with widespread expertise 
in the technique. Therefore, biomarkers identified and 
validated by IHC have an enormous potential for clinical 
translation. In surgical pathology, a range of biomarkers 
in clinical use is assessed by IHC7,8,33. 
Biomarkers identified by IHC have the advantage of 
defining the role of markers in the tissue context. They 
give insight into the expression of markers in specific 
cell types of tissue (malignant cells, stroma and adja-
cent normal cells or other cell types) and the distribu-
tion of the marker in subcellular compartments (nucle-
ar, membranous or cytoplasmic). Biomarker expression 
in a specific cell type (e.g. epithelial cells) or subcellular 
compartment (e.g. cytoplasm) might then be associated 
with tumour diagnosis. Biomarker expression in tumour 
can also be associated with the clinical follow-up (e.g. 
survival of patient) or the clinicopathologic characteris-
tics (e.g. lymph node invasion) of the patient34,35.
Over the last few decades many IHC biomarkers 
have been investigated for improving the diagnosis and 
prognosis of tumours. The diagnostic IHC biomarkers 
help in the diagnosis and sub-classification of tumours. 
IHC biomarker c-kit helps in the diagnosis of gastroin-
testinal stromal tumours (GISTs)9 and p63 helps to de-
tect the presence of basal cells which indicate normal 
prostate gland10,36. Furthermore, nuclear immunostain-
ing of ki-67 as a proliferation marker37, chromogranin 
A, CD56 and synaptophysin for the diagnosis of neuro-
endocrine tumours38,39 and the use of E-Cadherin in the 
differentiation of ductal and lobular carcinomas of the 
breast40 are used in clinical practice. 
An ideal diagnostic IHC biomarker should be 100% 
sensitive and specific which is almost never achieved as 
sensitivity increases at the expense of specificity and 
vice versa. The panel of biomarkers are thus becoming 
more relevant. These include CK20, P53, CK5/6, CD138, 
and Her2/Neu in the diagnosis of urothelial carcinoma 
in situ41; a panel of napsin-A, thyroid transcription factor 
1, Cytokeratin 5, and P63 in differentiating adenocarci-
noma from squamous cell carcinoma of the lung42,43 and 
a panel of S100P and XIAP in the differentiation of pan-
creatic cancer from non-neoplastic pancreatic tissue44,45.
In addition, IHC biomarkers are used for predicting 
the survival of patients, predicting the response to spe-
cific therapies and subsequent stratification of patients 
for different treatment options. Estrogen receptor (ER), 
progesterone receptor (PR) and HER-2/neu are used for 
the management of patients with breast cancer8,46-48. 
Panel of biomarkers are also used for prognostic and 
predictive purposes e.g. IHC4 (a panel of ER, PR, HER2 
and Ki-67) is an assay which estimates recurrence risk 
for early stage breast cancer patients49.
CONCLUSION
Careful identification of biomarkers and then vali-
dation in well-designed retrospective and prospective 
studies is a systematic strategy for developing clinically 
useful biomarkers. Immunohistochemistry biomarkers 
are useful tools that could potentially be translated to 
clinical practice if suitable biomarkers are identified and 
validated in independent cohorts.
REFERENCES
1. Biomarkers and surrogate endpoints: preferred defini1. 
Biomarkers Definitions Wroking Group. Biomarkers and 
surrogate endpoints: preferred definitions and conceptu-
al framework. Clin Pharmacol Ther 2001; 69:89-95.
2. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol 2012; 
6:140-6.
3. Frangogiannis NG. Biomarkers: hopes and challenges 
in th path from discovery to clinical practice. Transl Res 
2012; 159:197-204.
4. Lee JW, Figeys D, Vasilescu J. Biomarker assay translation 
from discovery to clinical studies in cancer drug develop-
ment: quantification of emerging protein biomarkers. Adv 
Cancer Res 2007; 96:269-98. 
5. Smith NR, Womack C. A matrix approach to guide IHC-
based tissue biomarker development in oncology drug 
discovery. J Pathol 2014; 232:190-8. 
6. Sim SC, Ingelman-Sundberg M. Pharmacogenomic bio-
markers: new tools in current and future drug therapy. 
Trends Pharmacol Sci 2011; 32:72-81.
7. O’Hurley G, Sjostedt E, Rahman A, Li B, Kampf C, Ponten 
F et al. Garbage in, garbage out: A critical evaluation of 
strategies used for validation of immunohistochemical 
biomarkers. Mol Oncol 2014; 8:783-98.
8. Allred DC. Issues and updates: evaluating estrogen re-
ceptor-alpha, progesterone receptor, and HER2 in breast 
cancer. Mod Pathol 2010; 23:S52-9.
9. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van 
Oosterom A, Hagemeijer A et al. Gastrointestinal stromal 
tumours (GISTs) negative for KIT (CD117 antigen) immu-
noreactivity. J Pathol 2004; 202:430-8.
10. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Com-
parison of the basal cell-specific markers, 34betaE12 and 
p63, in the diagnosis of prostate cancer. Am J Surg Pathol 
2002; 26:1161-8. 
11. Duffy MJ. Carcinoembryonic antigen as a marker for 
colorectal cancer: is it clinically useful? Clin Chem 2001; 
47:624-30.
12. Barry MJ. PSA screening for prostate cancer: the current 
controversy--a viewpoint. Patient Outcomes Research 
Team for Prostatic Diseases. Ann Oncol 1998; 9:1279-82.
JPMI VOL. 32 NO. 1 7
CANCER BIOMARKER DEVELOPMENT FROM BASIC SCIENCE TO CLINICAL PRACTICE
13. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery 
and validation: the long and uncertain path to clinical util-
ity. Nat Biotechnol 2006; 24:971-83.
14. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The 
interface between biomarker discovery and clinical vali-
dation: The tar pit of the protein biomarker pipeline. Pro-
teomics Clin Appl 2008; 2:1386-402.
15. Hustinx SR, Cao D, Maitra A, Sato N, Martin ST, Sudhir 
D et al. Differentially expressed genes in pancreatic duc-
tal adenocarcinomas identified through serial analysis of 
gene expression. Cancer Biol Ther 2004; 3:1254-61.
16. Castronovo V, Wang YH, Musmeci D, Dumont B, Turtoi 
A. Proteomic analysis of human pancreas cancers for the 
identification of targetable biomarkers. FASEB J 2010; 
24:424-8. 
17. Logsdon CD, Simeone DM, Binkley C, Arumugam T, 
Greenson JK, Giordano TJ et al. Molecular profiling of 
pancreatic adenocarcinoma and chronic pancreatitis 
identifies multiple genes differentially regulated in pan-
creatic cancer. Cancer Res 2003; 63:2649 - 57.
18. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van 
Heek NT, Rosty C, et al. Exploration of global gene expres-
sion patterns in pancreatic adenocarcinoma using cDNA 
microarrays. Am J Pathol 2003; 162:1151-62.
19. Chen JH, Ni RZ, Xiao MB, Guo JG, Zhou JW. Comparative 
proteomic analysis of differentially expressed proteins in 
human pancreatic cancer tissue. Hepatobiliary Pancreat 
Dis Int 2009; 8:193-200.
20. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic pro-
filing of pancreatic cancer for biomarker discovery. Mol 
Cell Proteomics 2005; 4:523-33. 
21. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein 
expression profiles in pancreatic adenocarcinoma com-
pared with normal pancreatic tissue and tissue affected 
by pancreatitis as detected by two-dimensional gel elec-
trophoresis and mass spectrometry. Cancer Res 2004; 
64:9018-26.
22. Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W et al. 
Expression and clinical significance of apolipoprotein E 
in pancreatic ductal adenocarcinoma. Med Oncol 2013; 
30:583.
23. Cummings J, Raynaud F, Jones L, Sugar R, Dive C. Fit-for-
purpose biomarker method validation for application 
in clinical trials of anticancer drugs. Br J Cancer 2010; 
103:1313-7.
24. Zapata M, Cohen C, Siddiqui MT. Immunohistochemical 
expression of SMAD4, CK19, and CA19-9 in fine needle 
aspiration samples of pancreatic adenocarcinoma: Utility 
and potential role. Cytojournal 2007; 4:13. 
25. Gao L, Antic T, Hyjek E, Gong C, Mueller J, Waxman I, et 
al. Immunohistochemical analysis of E-cadherin and zeste 
homolog 2 expression in endoscopic ultrasound-guided 
fine-needle aspiration of pancreatic adenocarcinoma. 
Cancer cytopathol 2013; 121:644-52.
26. Ali S, Cohen C, Little JV, Sequeira JH, Mosunjac MB, Sid-
diqui MT. The utility of SMAD4 as a diagnostic immuno-
histochemical marker for pancreatic adenocarcinoma, 
and its expression in other solid tumors. Diagn Cyto-
pathol 2007; 35:644-8.
27. Drucker E, Krapfenbauer K. Pitfalls and limitations in 
translation from biomarker discovery to clinical utility in 
predictive and personalised medicine. EPMA J 2013; 4:7.
28. Gnanapragasam VJ. Unlocking the molecular archive: the 
emerging use of formalin-fixed paraffin-embedded tissue 
for biomarker research in urological cancer. BJU Int 2010; 
105:274-8. 
29. Fairley JA, Gilmour K, Walsh K. Making the most of patho-
logical specimens: molecular diagnosis in formalin-fixed, 
paraffin embedded tissue. Curr Drug Targets 2012; 
13:1475-87.
30. Ioannidis JP, Panagiotou OA. Comparison of effect sizes 
associated with biomarkers reported in highly cited in-
dividual articles and in subsequent meta-analyses. J Am 
Med Asso 2011; 305:2200-10. 
31. Taylor CR. Standardization in immunohistochemistry: the 
role of antigen retrieval in molecular morphology. Bio-
technic Histoch 2006; 81:3-12.
32. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. 
Immunohistochemistry as an important tool in biomark-
ers detection and clinical practice. Biomark Insights 2010; 
5:9-20.
33. Jambhekar NA, Chaturvedi AC, Madur BP. Immunohisto-
chemistry in surgical pathology practice: a current per-
spective of a simple, powerful, yet complex, tool. Indian J 
Pathol Microbiol 2008; 51:2-11.
34. Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, 
Chou A et al. Histomolecular phenotypes and outcome 
in adenocarcinoma of the ampulla of vater. J Clin Oncol 
2013; 31:1348-56. 
35. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, 
Carter CR, et al. MicroRNA molecular profiles associated 
with diagnosis, clinicopathologic criteria, and overall sur-
vival in patients with resectable pancreatic ductal adeno-
carcinoma. Clin Cancer Res 2012; 18:534-45. 
36. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of 
immunohistochemical staining for p63, a sensitive marker 
of prostatic basal cells. Mod Pathol 2002; 15:1302-8.
37. Urruticoechea A, Smith IE, Dowsett M. Proliferation 
marker Ki-67 in early breast cancer. J Clin Oncol  2005; 
23:7212-20. 
38. Chang F, Vu C, Chandra A, Meenan J, Herbert A. Endo-
scopic ultrasound-guided fine needle aspiration cytology 
JPMI VOL. 32 NO. 1 8
CANCER BIOMARKER DEVELOPMENT FROM BASIC SCIENCE TO CLINICAL PRACTICE
of pancreatic neuroendocrine tumours: cytomorphologi-
cal and immunocytochemical evaluation. Cytopathology 
2006; 17:10-7. 
39. Gu M, Ghafari S, Lin F, Ramzy I. Cytological diagnosis of 
endocrine tumors of the pancreas by endoscopic ultra-
sound-guided fine-needle aspiration biopsy. Diagn Cyto-
pathol 2005; 32:204-10. 
40. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Dif-
ferential expression of E-cadherin in lobular and ductal 
neoplasms of the breast and its biologic and diagnostic 
implications. Am J Clin Pathol 2001; 115:85-98.
41. Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W 
et al. The role of immunohistochemistry in the diagnosis 
of flat urothelial lesions: a study using CK20, CK5/6, P53, 
Cd138, and Her2/Neu. Ann Diagn Pathol 2014; 18:27-32.
42. Brunnstrom H, Johansson L, Jirstrom K, Jonsson M, Jons-
son P, Planck M. Immunohistochemistry in the differential 
diagnostics of primary lung cancer: an investigation with-
in the Southern Swedish Lung Cancer Study. Am J Clin 
Pathol 2013; 140:37-46. 
43. Kosarac O, Takei H, Zhai QJ, Schwartz MR, Mody DR. 
S100P and XIAP expression in pancreatic ductal adeno-
carcinoma: potential novel biomarkers as a diagnostic ad-
junct to fine needle aspiration cytology. Acta Cytol 2011; 
55:142-8.
44. Ali A. Biomarkers for Pancreatic Cancer: Identification, 
Validation and Clinical application. Uni  Glasgow; 2015. 
Available at: http://theses.gla.ac.uk/6272/
45. Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Bill-
ingham LJ, Campbell FM et al. Estrogen receptor and pro-
gesterone receptor as predictive biomarkers of response 
to endocrine therapy: a prospectively powered pathology 
study in the Tamoxifen and Exemestane Adjuvant Multi-
national trial. J Clin Oncol 2011; 29:1531-8.
46. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen 
receptor status by immunohistochemistry is superior to 
the ligand-binding assay for predicting response to ad-
juvant endocrine therapy in breast cancer. J Clin Oncol 
1999; 17:1474-81. 
47. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of 
proteomic biomarkers into FDA approved cancer di-
agnostics: issues and challenges. Clin Proteomics 2013; 
10:13.
48. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E 
et al. Prognostic value of a combined estrogen recep-
tor, progesterone receptor, Ki-67, and human epidermal 
growth factor receptor 2 immunohistochemical score and 
comparison with the Genomic Health recurrence score in 
early breast cancer. J Clin Oncol 2011; 29:4273-8.
CONTRIBUTORS
AA conceived the idea, drafted the manuscript 
and gave final approval. ZA and YMY did literature 
review, drafted and critically revised the manuscript. 
KAO critically revised the manuscript and supervised 
the study. All authors contributed significantly to the 
submitted manuscript. 
